Efficacy of de-escalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial Oleg Gluz 1,2,3 , Cornelia Kolberg-Liedtke 4 , Aleix Prat 5,6 , Matthias Christgen 7 , Daniel Gebauer 8 , Ronald Kates 1 , Laia Paré 5,6 , Eva-Maria Grischke 9 , Helmut Forstbauer 10 , Michael Braun 11 , Mathias Warm 12 , John Hackmann 13 , Christoph Uleer 14 , Bahriye Aktas 15,16 , Claudia Schumacher 17 , Sherko Kuemmel 18 , Rachel Wuerstlein 1,19 , Enrico Pelz 8 , Ulrike Nitz 1,2 , Hans Heinrich Kreipe 7 , Nadia Harbeck 1,19 . 1. West German Study Group, Moenchengladbach, Germany; 2. Ev. Hospital Bethesda, Breast Center Niederrhein, Moenchengladbach, Germany; 3. University Clinics Cologne, Cologne, Germany; 4. Charité, Women’s Clinic, Berlin, Germany; 5. Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain; 6. Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; 7. Medical School Hannover, Institute of Pathology, Hannover, Germany; 8. Institute of Pathology Viersen, Viersen, Germany; 9. University Clinics Tuebingen, Women’s Clinic, Tuebingen, Germany; 10. Practice Network Troisdorf, Troisdorf, Germany; 11. Rotkreuz Clinics Munich, Breast Center, Munich, Germany; 12. City Hospital Holweide, Breast Center, Cologne, Germany; 13. Marien-Hospital, Breast Center, Witten, Germany; 14. Practice of Gynecology and Oncology, Hildesheim, Germany; 15. University Clinics Essen, Women’s Clinic, Essen, Germany; 16. University Clinics Leipzig, Women’s Clinic, Leipzig, Germany; 17. St. Elisabeth Hospital, Breast Center, Cologne, Germany, 18. Clinics Essen Mitte, Breast Center, Essen, Germany; 19. Breast Center, Dept. OB&GYN, University of Munich (LMU) and CCCLMU, Munich, Germany Corresponding author: Dr. Oleg Gluz, MD Breast Center Niederrhein Bethesda Clinics, West German Study Group Ludwig Weber Str. 15, 41061 Moenchengladbach, Germany and University of Cologne, Germany; Phone: +49 2161 9812330; Fax: +49 2161 5662319; E-mail: oleg.gluz@wsg-online.com Running title: Chemotherapy efficacy according to immune/proliferation genes Keywords: TNBC, ADAPT, HER2, de-escalated chemotherapy, nab-paclitaxel, gemcitabine, carboplatin, immune markers, PAM50 Abbreviations: A/T: anthracycline/taxane; carbo: carboplatin; CHT: chemotherapy; EFS: event free survival; gem: gemcitabine; IHC: immunohistochemistry; nab-pac: nab-paclitaxel; NACT: neoadjuvant chemotherapy; OS: overall survival; pCR: pathological complete response; TNBC: triple negative breast cancer Authors disclosures: This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ijc.32488 This article is protected by copyright. All rights reserved.